Neurogenic inflammation in the context of migraine
- 6 April 2001
- journal article
- review article
- Published by Wiley in Microscopy Research and Technique
- Vol. 53 (3) , 167-178
- https://doi.org/10.1002/jemt.1081
Abstract
Despite considerable research into the pathogenesis of idiopathic headaches, such as migraine, the pathophysiological mechanisms underlying them remain poorly understood. Although it is well established that the trigeminal nerve becomes activated during migraine, the consequences of this activation remain controversial. One theory, based on preclinical observations, is that activation of trigeminal sensory fibers leads to a painful neurogenic inflammation within the meningeal (dural) vasculature mediated by neuropeptide release from trigeminal sensory fibres and characterized by plasma protein extravasation, vasodilation, and mast cell degranulation. Effective antimigraine agents such as ergots, triptans, opioids, and valproate inhibit preclinical neurogenic dural extravasation, suggesting that this activity may be a predictor of potential clinical efficacy of novel agents. However, several clinical trials with other agents that inhibit this process preclinically have failed to show efficacy in the acute treatment of migraine in man. Alternatively, it has been proposed that painful neurogenic vasodilation of meningeal blood vessels could be a key component of the inflammatory process during migraine headache. This view is supported by the observation that jugular plasma levels of the potent vasodilator, calcitonin gene‐related peptide (CGRP) are elevated during the headache and normalized by successful sumatriptan treatment. Preclinically, activation of trigeminal sensory fibers evokes a CGRP‐mediated neurogenic dural vasodilation, which is blocked by dihydroergotamine, triptans, and opioids but unaffected by NK1 receptor antagonists that failed in clinical trials. These observations suggest that CGRP release with associated neurogenic dural vasodilation may be important in the generation of migraine pain, a theory that would ultimately be tested by the clinical testing of a CGRP receptor antagonist. Microsc. Res. Tech. 53:167–178, 2001.Keywords
This publication has 79 references indexed in Scilit:
- Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraineLife Sciences, 1997
- Transnasal ButorphanolDrugs, 1995
- Diagnosis and Optimum Treatment of MigraineCNS Drugs, 1994
- Superior mesenteric artery blood flow in man measured with intra-arterial Doppler catheters: Effect of octreotideJournal of Hepatology, 1993
- Lack of asymmetry of middle cerebral artery blood velocity in unilateral migraine.Stroke, 1993
- Evidence for the presence of 5-HT1B receptor messenger RNA in neurons of the rat trigeminal gangliaEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- Evidence for 5-HT1B/1D Receptors Mediating the Antimigraine Effect of Sumatriptan and DihydroergotamineCephalalgia, 1991
- Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptanThe Lancet, 1991
- Modulation of neurogenic inflammation: novel approaches to inflammatory diseaseTrends in Pharmacological Sciences, 1990
- Neuronal pathways to the rat middle meningeal artery revealed by retrograde tracing and immunocytochemistryJournal of the Autonomic Nervous System, 1989